Research title: Systems biology of drug resistance and metastasis
Research summary: The major research themes in my lab are systems-level analysis of therapy resistance and metastasis mainly in breast cancer. Importantly, how epithelial-mesenchymal transition (EMT), which is an important initiator step in metastasis, contributes to drug resistance and how we can use this knowledge to better target cancer cells is another focus in my lab. Two most aggressive subtypes of breast cancer, HER2-overexpressing and triple negative breast cancers (TNBCs) as well as ER+ breast cancer are the major disease-foci. In addition to breast cancer, we work on the molecular pathogenesis of gastrointestinal stromal tumors (GISTs).
In this line, we develop:
- Transgenic and syngeneic transplantation mouse models of acquired drug resistance;
- Primary/established cell line models of acquired drug resistance to combinatorial therapies in 3-D culture;
- Different experimental and spontaneous metastasis models in mice.
Combining these models with high-throughput transcriptomics/proteomics approaches, bioinformatics/modeling tools and clinical sample analysis, my research group is aiming at identifying novel targets overcoming resistance to state-of-art clinically-applied or -tested drugs and preventing metastatic spread of breast cancer. At molecular level, two major foci are proteins and non-coding RNAs, especially microRNAs in my lab.
Research keywords: breast cancer / systems biomedicine / therapy resistance / metastasis / microRNAs / GISTs
|Phone||:||+90 312 290 2402|
|Fax||:||+90 312 266 5097|